ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy
May 6, 2015 7:42 AM EDT
GlaxoSmithKline (NYSE: GSK) reported Q1 EPS of GBP1.67, versus GBP0.14 reported last year. Revenue for the quarter came in at GBP5.62 million, versus GBP5.61 million reported last year.
Through application of the strategy set out in 2008 and the recently completed transaction with Novartis, GSK has created a new balanced group of world-leading businesses in Vaccines, Pharmaceuticals and Consumer Healthcare, which has broadened GSKs scope to improve human health. In an update to investors today, GSK set out prospects for the newly shaped Group.
Sir Andrew Witty, Chief Executive Officer, GSK... More
May 6, 2015 7:03 AM EDT
ViiV Healthcare announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV. The Phase III programme comprises two replicate studies evaluating 48 week viral suppression with a two drug regimen combining an integrase inhibitor (dolutegravir) and a non-nucleoside reverse transcriptase inhibitor (rilpivirine) in patients with HIV who have already achieved viral suppression with a three drug regimen.
"As HIV care becomes an increasingly long term consideration, patients and clinicians are seeking... More
